NCT02022501View on ClinicalTrials.gov

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 21, 2016

Study Completion Date

April 21, 2016

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

DE-120

Trial Locations (3)

Unknown

Bakersfield

Beverly Hills

Dallas

All Listed Sponsors
lead

Santen Inc.

INDUSTRY

NCT02022501 - A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter